Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- Covid-19: Assocham suggests war-footing steps; seeks moratorium on all debt repayments – Times of India
- Primus Partners’ FY 2023-24 report reveals 44.8% revenue growth and strategic global expansion under the ‘CHETNA’ framework
- Can injections be needle-free, painless? This Pune-based firm has the answer
- ‘Andhra Pradesh set to lead South Asia in data revolution’: Nara Lokesh
